Compare Eli Lilly And Co (LLY) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Eli Lilly And Co is far larger — about 11010× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| LLY | MSTZ | |
|---|---|---|
Market Cap | $1.04T | $94.46M |
Volume | 3,064,878 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.28K | $27.92 |
52-Week Low | $799.57 | $2.29 |
Typical Hold Time | 93 Days | 8 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
MSTZ trades at $2.62, down 1.5% today, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The stock faces resistance at $3 with support at $2, indicating a tight trading range. Recent ETF coverage highlights its inclusion in leveraged fund discussions, though specific company fundamentals remain undisclosed in available data.
The outlook for MSTZ hinges on upcoming financial disclosures to clarify valuation metrics like P/E and profitability. Key risks include limited public financial data and market volatility. Investors await earnings reports to assess growth potential amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
